Skip to main content

Table 2 Parameters input in the model and their ranges used in the sensitivity analyses

From: A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society

 

Base-case values

Range

 

Capecitabine

Observation

Lower

Upper

Rule

Distributionc

Capecitabine for the first year ($/month)

306.48

0

26.84

306.48

Rangea

Gamma

Monitoring safety of capecitabine therapy in the first year ($/month)

46.83

0

37.46

56.20

 ± 20%

Gamma

Treatment after relapse ($/month)b

1546.43

0

773.22

2319.65

 ± 50%

Gamma

Routine follow-up ($/month)

 

  < 3 years

38.39

30.71

46.07

 ± 20%

Gamma

 3–5 years

21.32

17.06

25.58

 ± 20%

Gamma

  > 5 years

12.78

10.22

15.34

 ± 20%

Gamma

Time cost ($/month)

 

  < 1 year

49.97

16.66

39.97 (capecitabine)

13.33 (observation)

59.96 (capecitabine)

19.99 (observation)

 ± 20%

Gamma

 1–2 years

16.66

13.33

19.99

 ± 20%

Gamma

 3–5 years

8.33

6.66

10.0

 ± 20%

Gamma

  > 5 years

4.16

3.33

4.99

 ± 20%

Gamma

Travel cost ($/month)

 

  < 1 year

12.37

4.12

9.90 (capecitabine)

3.30 (observation)

14.84 (capecitabine)

4.94 (observation)

 ± 20%

Gamma

 1–2 years

4.12

3.30

4.94

 ± 20%

Gamma

 3–5 years

2.06

1.65

2.47

 ± 20%

Gamma

  > 5 years

1.03

0.82

1.24

 ± 20%

Gamma

Management of grade 3/4 adverse events ($/case)

 

 Hand-foot syndrome

15.46

-

12.37

18.55

 ± 20%

Gamma

 Diarrhea

44.30

-

28.50

54.60

[45]

Gamma

Incidence rate of grade 3/4 adverse events, %

 

 Hand-foot syndrome

13.45

0

11.44

15.47

95% CI

Beta

 Diarrhea

3.19

0

2.15

4.22

95% CI

Beta

Utility

 

 DFS

0.80

0.73

0.87

[48]

Beta

 Relapse

0.73

0.66

0.8

[48]

Beta

Disutility of grade 3/4 adverse events

 

 Hand-foot syndrome

0.12

-

0.096

0.144

 ± 10%

Beta

 Diarrhea

0.10

-

0.08

0.12

 ± 10%

Beta

 Annual discount rate, %

5

0

10

-

 

 Transition probability, %

Model fit

-

-

5%

Uniform

  1. -, not applicable
  2. aThe range of capecitabine cost was set as the lowest and highest unit price from the Chinese Drug Bidding Database
  3. bThe monthly cost after relapse was estimated based on the monthly average treatment cost of relapsed cases in Sun Yat-sen University Cancer Center
  4. cThe distributions were applied in the probabilistic sensitivity analysis
  5. 95% CI 95% confidence interval, DFS Disease-free survival